Efficacy and Feasibility of Ectoin® Inhalation Solution in Inflammatory Obstruction and Ageing of the Lung

Inclusion Criteria: * Postmenopausal females (75 - 80 years) * FEV1/FVC \< 0,77 (in the investigation 2007/2008) * Inflammatory markers TFN-alpha \> median or neutrophilic granulocytes \> median (investigation 2007/2008) * Non smokers or ex smokers who have stopped smoking for longer than 6 months Exclusion Criteria: * Participation in another clinical study in the previous month * Severe concomitant disease which may have an impact on the study participation * Hypersensitivity against Ectoin * Myocardial infarction or apoplexy within the last year * Uncontrolled hypertension: systolic blood pressure \>200 mmHg or diastolic pressure \>120 mmHg * Known aortic aneurysm * Other respiratory diseases (e.g. cystic fibrosis, alpha-1-Antitrypsin deficiency, sarcoidosis, allergic alveolitis, tuberculosis, etc.) * Patients who have had treatment with live attenuated vaccinations within 14 days prior to screening visit (Inactivated influenza vaccination is acceptable, provided it is not administered within 7 days prior to screening visit) * on investigators decision